- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01072916
Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)
The Role of Serine-Proteases in Gastrointestinal Function and Irritable Bowel Syndrome
The proposed pilot project for this seed grant focuses on the role of intestinal serine-proteases in the pathogenesis of diarrhea-predominant IBS (D-IBS). In this study we will further assess serine-protease activity in patients with D-IBS and also explore a possible mechanism by which these proteases can lead to alterations in intestinal physiology and symptoms in these patients.
The general hypotheses for the proposed research are that (A) the levels of fecal serine-protease in patients with D-IBS are abnormally increased (B) this abnormal serine-protease activity leads to/is associated with an abnormal increase in intestinal permeability and therefore enables (C) chronic stimulation and activation of the mucosal immune system in these patients. In addition, it is aim to determine whither periodontal inflammation is associated with intestinal permeability and serine protease activity.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7080
- University of North Carolina at Chapel Hill, Program in Digestive Health and the Department of Gastroenterology and Hepatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any sex, race, or ethnicity.
- At least 18 years of age (no upper age limit).
- D-IBS patients must meet Rome III criteria for IBS and must have been evaluated by a physician to exclude other diseases that could explain the symptoms. For the latter, patients self statement is acceptable (no official document is required).
- Participation in Dr. Whitehead's 'heterogeneity of IBS' and/or Dr. Ringel's 'intestinal inflammation in patients with D-IBS' research study.
Exclusion Criteria:
- Healthy controls must have no significant or recurring gastrointestinal symptoms.
- Patients and healthy controls should not have a serious, unstable medical condition.
- Patients and healthy controls must have had no gastrointestinal tract surgery other than appendectomy or cholecystectomy.
- Patients and healthy controls must not be pregnant (by self-report). Pregnant women will not be allowed to participate as pregnancy can affect gastrointestinal symptoms.
- Patients and healthy controls must not have a history of inflammatory bowel disease, celiac disease, or other diagnosis that could explain chronic or recurring bowel symptoms in IBS patients or controls.
- Patients and healthy controls should have no history of lactose malabsorption (by self-report).
- Patients and healthy controls should have no history of clinical symptoms of acute infections during the last 8 weeks prior to enrolment in the study.
- Patients and healthy controls should have no history of anti-inflammatory agents including aspirin, non-aspirin, non-steroid anti-inflammatory (NSAID) or steroids in the last four weeks prior to study enrollment.
- Patients should not intentionally consume probiotics or undergo antibiotic treatment during the last 4 weeks prior to enrolment in the study. If the subject consumed any of these medications, a washout period of 4 weeks will be required).
- Patients must have no history of fainting or light headedness during periods of fasting.
- Patients must not have diabetes mellitus, or any similar conditions, that would cause an adverse reaction to the sugar drink.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
IBS
Subjects with IBS-D
|
Healthy
Healthy Subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
fecal serine protease activity
Time Frame: protease activity determined at at recruitment
|
we will use an elisa-based method to measure the activity of serine proteases in fecal samples from IBS and HC subjects
|
protease activity determined at at recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intestinal permeability
Time Frame: 6hrs following recruitment
|
We will analyze sugar concentrations in urine to determine the level of intestinal permeability.
|
6hrs following recruitment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ian M Carroll, PhD, UNC Chapel Hill Department of Gastroenterology and Hepatology
Publications and helpful links
General Publications
- Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007 Jul;133(1):24-33. doi: 10.1053/j.gastro.2007.04.005. Epub 2007 Apr 14.
- Roka R, Rosztoczy A, Leveque M, Izbeki F, Nagy F, Molnar T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, Bueno L. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007 May;5(5):550-5. doi: 10.1016/j.cgh.2006.12.004. Epub 2007 Mar 2.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08-1149
- R24DK067674 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon, Irritable
-
University of NottinghamQuadram Institute BioscienceRecruitingColon, IrritableUnited Kingdom
-
GlaxoSmithKlineCompletedIrritable ColonUnited Kingdom
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedIrritable Bowel Syndrome (IBS) | Irritable ColonUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedIrritable ColonUnited States, Spain, South Africa, Sweden, Australia, Canada, Germany, United Kingdom, France, Netherlands
-
GlaxoSmithKlineCompletedIrritable Bowel Syndrome (IBS) | Irritable ColonUnited States, Australia
-
GlaxoSmithKlineCompletedIrritable Bowel Syndrome (IBS) | Irritable ColonUnited States, Australia
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedInflammation | Irritable Bowel Syndrome | Colonic Diseases, Functional | Colon, IrritableUnited States